Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, HTG Molecular Diagnostics Partner to Develop CDx Tests for Pharma

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and Qiagen Manchester Ltd., a wholly owned subsidiary of Qiagen, said today that they have inked a master assay development, commercialization, and manufacturing agreement.

The agreement creates a framework for the companies to combine their technological and commercial strengths to offer pharmaceutical companies a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests, with a focus on oncology.

As part of the agreement, Qiagen North American Holdings, another Qiagen subsidiary, has made a minority investment of an undisclosed amount in HTG.

"Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics and we believe this agreement accelerates both companies' efforts. We are excited to offer this solution to customers," HTG President and CEO TJ Johnson said in a statement.

"HTG's extraction-free technology can add attractive capabilities to Qiagen's NGS-based sample-to-insight solutions for applications in pathology where sample often is limited," Kai te Kaat, vice president and head of franchise oncology for Qiagen's molecular diagnostics business area, added in a statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.